CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 10 enrolled
Drug / intervention
Golimumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04200833
NCT04200833N/ACompleted
CompareCT.gov

Golimumab in Juvenile Idiopathic Arthritis-associated Uveitis Failing Adalimumab

Medical University of Graz·observational·Posted Dec 16, 2019·Updated May 5, 2022

In Brief

An observational study evaluating Golimumab for JIA Associated Uveitis. Completed, enrolled 10 participants.

Detailed Summary

To asses the use of golimumab, a fully humanized anti-TNF Alpha monoclonal antibody, in juvenile idiopathic Arthritis-associated uveitis refractory to adalimumab.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsJIA Associated Uveitis
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 16, 2019
Enrollment StartMar 1, 2010
Primary CompletionJul 1, 2021
Study CompletionAug 1, 2021
TodayJul 2, 2026
Enrollment to primary: 11.3 yearsPosted 6.5 years ago

Interventions

Golimumabdrug

subcutaneous injection